이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

태아 및 신생아의 중증 용혈성 질환(HDFN) 위험이 있는 임신에서 니포칼리맙에 대한 연구 (AZALEA)

2026년 11월 2일 업데이트: Janssen Research & Development, LLC

태아 및 신생아의 중증 용혈성 질환(HDFN) 위험이 있는 임신에서 니포칼리맙의 효능 및 안전성을 평가하기 위한 3상 무작위, 위약 대조, 이중맹검, 다기관 연구

The purpose of this study is to assess the effectiveness of nipocalimab when compared to placebo in decreasing the risk of fetal anemia (a condition in which a baby's red blood cell volume falls below normal levels while the baby is developing in the womb) with live neonates in pregnant participants at risk for severe hemolytic disease of the fetus and newborn.

연구 개요

연구 유형

중재적

등록 (추정된)

120

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Leiden, 네덜란드, 2333 ZA
        • 모병
        • Leiden University Medical Center
      • Berlin, 독일, 10117
        • 모병
        • Charite Universitaetsmedizin Berlin
      • Giessen, 독일, 35392
        • 모병
        • Universitaetsklinikum Giessen und Marburg Standort Giessen
      • Hamburg, 독일, 20251
        • 모병
        • Universitaetsklinikum Hamburg Eppendorf
    • California
      • La Jolla, California, 미국, 92037
        • 모병
        • University of California at San Diego
      • Los Angeles, California, 미국, 90027
        • 모병
        • Kaiser Permanente Los Angeles Medical Center
      • Sacramento, California, 미국, 95817
        • 모병
        • UC Davis School of Medicine
    • Colorado
      • Aurora, Colorado, 미국, 80045
        • 모병
        • Childrens Hospital Colorado
    • Florida
      • Miami, Florida, 미국, 33136
        • 모병
        • University of Miami
    • Illinois
      • Park Ridge, Illinois, 미국, 60068
        • 모병
        • Advocate Children's Hospital
    • Indiana
      • Indianapolis, Indiana, 미국, 46202
        • 정지된
        • Riley Children s Hospital
    • Iowa
      • Iowa City, Iowa, 미국, 52242
        • 모병
        • University of Iowa
    • Kentucky
      • Lexington, Kentucky, 미국, 40536
        • 모병
        • University of Kentucky Medical Center
    • Maryland
      • Baltimore, Maryland, 미국, 21287
        • 모병
        • Johns Hopkins Hospital
    • Massachusetts
      • Boston, Massachusetts, 미국, 02115
        • 모병
        • Boston Childrens Hospital
    • Minnesota
      • Minneapolis, Minnesota, 미국, 55404
        • 모병
        • Midwest Fetal Care Center
    • New York
      • New York, New York, 미국, 10032
        • 모병
        • Columbia University Medical Center
    • North Carolina
      • Chapel Hill, North Carolina, 미국, 27599-7516
        • 모병
        • University of North Carolina (UNC) - School of Medicine
    • Ohio
      • Cincinnati, Ohio, 미국, 45267
        • 모병
        • University of Cincinnati
    • Oregon
      • Portland, Oregon, 미국, 97239
        • 모병
        • Oregon Health and Science University
    • Pennsylvania
      • Allentown, Pennsylvania, 미국, 18103-6218
        • 모병
        • Lehigh Valley Hospital
    • Texas
      • Austin, Texas, 미국, 78723
        • 모병
        • University of Texas Dell Medical School Department of Women's Health
      • Galveston, Texas, 미국, 77555
        • 모병
        • University Of Texas Medical Branch At Galveston
    • Utah
      • Murray, Utah, 미국, 84107
        • 모병
        • Intermountain Medical Center
    • Virginia
      • Norfolk, Virginia, 미국, 23507
        • 모병
        • Macon & Joan Brock Virginia Health Sciences at Old Dominion University
    • Washington
      • Seattle, Washington, 미국, 98105
        • 모병
        • Seattle Children's Hospital
      • Brussels, 벨기에, 1020
        • 모병
        • C.H.U. Brugmann
      • Leuven, 벨기에, 3000
        • 모병
        • Universitair Ziekenhuis Leuven
      • Belo Horizonte, 브라질, 30130 100
        • 모병
        • Faculdade de Medicina Universidade Federal de Minas Gerais
      • Goiânia, 브라질, 74605 020
        • 모병
        • Hospital das Clinicas - UFG
      • Recife, 브라질, 50070902
        • 모병
        • Instituto de Medicina Integral Professor Fernando Figueira
      • Rio de Janeiro, 브라질, 22281 100
        • 모병
        • IDOR - Regional Rio de Janeiro
      • São Paulo, 브라질, 05403-010
        • 모병
        • Hospital Das Clinicas Da Faculdade De Medicina Da USP
      • Stockholm, 스웨덴, 14186
        • 모병
        • Karolinska Universitetssjukhuset Huddinge
      • Barcelona, 스페인, 08035
        • 모병
        • Hosp Univ Vall D Hebron
      • Madrid, 스페인, 28046
        • 모병
        • Hosp. Univ. La Paz
      • Seville, 스페인, 41013
        • 모병
        • Hosp. Virgen Del Rocio
      • Buenos Aires, 아르헨티나, C1199
        • 모병
        • Hospital Italiano de Buenos Aires
      • Córdoba, 아르헨티나, X5016KEH
        • 모병
        • Hospital Privado Universitario De Cordoba
      • Dublin, 아일랜드, D01 P5W9
        • 모병
        • Rotunda Hospital
      • Birmingham, 영국, B15 2TG
        • 모병
        • Birmingham Women's Hospital
      • Leeds, 영국, LS9 7TF
        • 모병
        • Leeds Teaching Hospitals NHS Trust
      • London, 영국, SE5 9RS
        • 모병
        • Kings College Hospital
      • London, 영국, SW17 0QT
        • 모병
        • St Georges Hospital
      • Manchester, 영국, M13 9WL
        • 모병
        • St.Mary's Hospital
      • Oxford, 영국, OX3 9DU
        • 모병
        • John Radcliffe Hospital
      • Graz, 오스트리아, 8036
        • 모병
        • Medizinische Universitaet Graz
      • Vienna, 오스트리아, 1090
        • 모병
        • Medizinische Universitaet Wien
      • Jerusalem, 이스라엘, 91240
        • 모병
        • Hadassah mount scopus
      • Petah Tikva, 이스라엘, 49100
        • 모병
        • Rabin Medical Center
      • Ramat Gan, 이스라엘, 5265601
        • 모병
        • The Chaim Sheba Medical Center
      • Roma, 이탈리아, 00168
        • 모병
        • Fondazione Policlinico Universitario A Gemelli IRCCS
      • Fukuoka, 일본, 812 8582
        • 완전한
        • Kyushu University Hospital
      • Gifu, 일본, 500-8717
        • 모병
        • Gifu Prefectural General Medical Center
      • Izumi-shi, 일본, 594-1101
        • 모병
        • Osaka Womens and Childrens Hospital
      • Sendai, 일본, 989-3126
        • 완전한
        • Miyagi Childrens Hospital
      • Ōta-ku, 일본, 143-8541
        • 모병
        • Toho University Medical Center Omori Hospital
    • British Columbia
      • Vancouver, British Columbia, 캐나다, V6H 3N1
        • 모병
        • BC Women's Hospital University of British Columbia
    • Ontario
      • Toronto, Ontario, 캐나다, M5G 1X5
        • 모병
        • Mount Sinai Hospital
    • Quebec
      • Montreal, Quebec, 캐나다, H4A 3J1
        • 모병
        • McGill University Health Centre
      • Montreal, Quebec, 캐나다, H3T 1C5
        • 모병
        • Centre Hospitalier Sainte Justine
      • Lodz, 폴란드, 93 338
        • 모병
        • Instytut Centrum Zdrowia Matki Polki
      • Warsaw, 폴란드, 01 211
        • 모병
        • Instytut Matki i Dziecka
      • Warsaw, 폴란드, 02 507
        • 모병
        • Panstwowy Instytut Medyczny MSWiA w Warszawie
      • Bron, 프랑스, 69500
        • 모병
        • Hospices Civils de Lyon - Groupement Hospitalier Est - Hopital Femme Mere Enfant
      • Lille, 프랑스, 59000
        • 모병
        • CHRU Lille
      • Paris, 프랑스, 75012
        • 모병
        • Hopital Armand Trousseau
      • South Brisbane, 호주, 4101
        • 모병
        • Mater Hospital Brisbane
      • Sydney, 호주, 2170
        • 모병
        • Liverpool Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

설명

Inclusion Criteria:

  • Pregnant and an estimated gestational age (GA) (based on ultrasound dating) from Week 13^0/7 to Week 18^6/7 at randomization

  • History of severe Hemolytic Disease of the Fetus and Newborn (HDFN) in a prior pregnancy defined as documented:

    1. fetal anemia as result of HDFN or fetal hydrops as result of HDFN or received greater than or equal to (>=)1 IUT as a result of HDFN or
    2. fetal loss or neonatal death as a result of HDFN, with maternal alloantibody titers for Rhesus antigen D protein (RhD), Kell, Kell Rhesus antigen C protein (Rhc), Rhesus antigen E protein (RhE), or RhC antigen above the critical levels (anti-Kell >=4; other >=16) and evidence of an antigen-positive fetus
  • During the current pregnancy, presence of maternal alloantibody to RhD, Rhc, RhE, or RhC antigen with titers above the critical level (anti-Kell >= 4; other >=16) based on the designated central lab results at screening

  • Evidence of antigen-positivity corresponding to the current maternal alloantibody (RhD, Kell, Rhc, RhE, or RhC) confirmed by non-invasive antigen cell-free fetal DNA (cffDNA) performed at the central laboratory

  • Have screening lab test results within values within the study protocol-specified parameters: a) albumin >= lower limit of normal (LLN); b) alanine transaminase (AST) less than or equal to (<=) 2 × upper limit of normal (ULN); c) alanine transaminase (ALT) <=2 × ULN d) creatinine <=0.8 milligrams per deciliter (mg/dL), SI: <=70.7 micromole per liter (μmol/L), and Serum total immunoglobulins G (IgG) ≥ 600 mg/dL SI: >=6 g/L

  • Medically stable on the basis of physical examination, medical history, vital signs, 12-lead ECG, and clinical lab tests performed at screening

Exclusion Criteria:

  • Currently pregnant with a multiple gestation (twins or more)
  • Evidence of fetal anemia prior to randomization in the current pregnancy
  • History of severe preeclampsia prior to GA Week 34 or severe fetal growth restriction (estimated fetal weight <3rd percentile, based on local fetal growth normative standards) in a previous pregnancy
  • Current uncontrolled hypertension
  • History of myocardial infarction, unstable ischemic heart disease, or stroke
  • Has any confirmed or suspected clinical immunodeficiency syndrome or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant
  • Has inflammatory or autoimmune diseases requiring immunosuppressive therapies that may jeopardize the safety of the participant
  • Currently has a malignancy or has a history of malignancy within 3 years before screening (with the exception of localized basal cell carcinoma and/or squamous cell carcinoma skin cancer that has been adequately treated with no evidence of recurrence for at least 3 months before the first study intervention administration or cervical carcinoma in situ that has been treated with no evidence of recurrence for at least 3 months before the first study intervention)
  • Is currently receiving systemic corticosteroids or other immunosuppressants for disorders unrelated to the pregnancy
  • Has received or planning to receive plasmapheresis, immunoadsorption therapy, intravenous immunoglobulin (IV Ig), or any immunoglobulin (Ig)G fragment crystallizable (Fc)-related protein therapeutics during the current pregnancy
  • Has a severe infection including opportunistic infections
  • Presence of abnormal (protocol-specified) hematologic lab values during screening
  • History of an unprovoked pulmonary embolism or history of recurrent deep vein thrombosis (DVT)

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Nipocalimab

Participants will receive nipocalimab intravenously (IV) once weekly (qw) from randomization through gestational age (GA) Week 35.

Nipocalimab will be administered as an intravenous infusion.

다른 이름들:
  • JNJ-80202135
  • M281
  • JNJ-86507083
위약 비교기: Placebo

Participants will receive matching placebo IV qw from randomization through GA Week 35.

Placebo will be administered as an intravenous infusion.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Percentage of Pregnancies That did not Result in Fetal Loss, Intrauterine Transfusion (IUT), Hydrops Fetalis, or Neonatal Death
기간: From randomization in the study through 4 weeks of age or 41 weeks Postmenstrual Age (PMA) during neonatal period, whichever is later

Percentage of pregnancies that did not result in fetal loss, IUT, hydrops fetalis, or neonatal death (during the neonatal period) will be reported. Hydrops fetalis is defined as the presence of greater than or equal to(>=)2 abnormal fluid collections in the fetus or neonate, such as ascites, pleural effusions, pericardial effusion, and generalized skin edema (skin thickness greater (>)5 millimeter [mm]). PMA is the time elapsed between the first day of the last menstrual period and birth (gestational age) plus the time elapsed after birth (chronological age).

From randomization in the study through 4 weeks of age or 41 weeks Postmenstrual Age (PMA) during neonatal period, whichever is later

2차 결과 측정

결과 측정
측정값 설명
기간
Number of Participants With Hemolytic Disease of the Fetus and Newborn (HDFN) by Severity
기간: For first database lock: from randomization in the study through 4 weeks of age or 41 weeks PMA during neonatal period, whichever is later for the first database lock; for second database lock: through 12 weeks after birth

Number of participants with HDFN by severity will be reported. The severity of HDFN is defined as: 5 (fatal): fetal or neonatal death due to any reason; 4 (severe): hydrops fetalis (in fetus or newborn) or receiving IUT during pregnancy as a result of HDFN but not 5 (fatal); 3 (moderate): neonatal exchange transfusions received as a result of HDFN related hemolysis and jaundice but not 4 (severe) or 5 (fatal); 2 (mild): neonatal simple transfusions received due to HDFN after birth, with or without phototherapy, but not 3 (moderate), 4 (severe), or 5 (fatal); and 1 (minimal or none): not in 2 (mild), 3 (moderate), 4 (severe), or 5 (fatal) as described above. Here database lock implies the last participant has given birth or terminated their pregnancy, completed the Week 4 visit after delivery, and whose neonate has also completed the Week 4 visit (or 41 weeks PMA, whichever is later) or died prior to this timepoint.

For first database lock: from randomization in the study through 4 weeks of age or 41 weeks PMA during neonatal period, whichever is later for the first database lock; for second database lock: through 12 weeks after birth
Time to First Occurrence of IUT or Hydrops Fetalis
기간: From randomization to delivery of baby (Up to 38 weeks)

Time to first occurrence of IUT or hydrops fetalis will be reported.

From randomization to delivery of baby (Up to 38 weeks)
Neonatal Mortality and Morbidity Index (NMMI) in Liveborn Neonates
기간: Through 38 weeks PMA or at discharge if earlier than 38 weeks PMA

The NMMI will be assessed with the following categories: fatal: fetal/neonatal death; major morbidity: any of intraventricular hemorrhage grade 3/4, seizures, hypoxic-ischemic encephalopathy, necrotizing enterocolitis stage 2/3, respiratory distress syndrome requiring mechanical ventilation, bronchopulmonary dysplasia requiring oxygen support, or persistent pulmonary hypertension; Minor morbidity: anemia requiring simple transfusion, hyperbilirubinemia requiring an exchange transfusion, hypotension requiring treatment, intraventricular hemorrhage grade 1/2, necrotizing enterocolitis stage 1, or respiratory distress syndrome not requiring mechanical ventilation; None: no major or minor morbidities described above. Hyperbilirubinemia requiring phototherapy will be classified in this category'

Through 38 weeks PMA or at discharge if earlier than 38 weeks PMA
Number of IUT's Received During the Pregnancy
기간: From randomization to delivery of baby (Up to 38 weeks)

Number of IUT's received during the pregnancy will be reported.

From randomization to delivery of baby (Up to 38 weeks)
Percentage of Pregnancies With Fetal Loss
기간: Time to delivery of baby (Up to 38 weeks)

Percentage of pregnancies with fetal loss will be reported.

Time to delivery of baby (Up to 38 weeks)
Percentage of Pregnancies With Fetal or Neonatal Death
기간: Through Week 4 or 41 weeks PMA

Percentage of pregnancies with fetal or neonatal death (through the neonatal period) as a result of HDFN will be reported.

Through Week 4 or 41 weeks PMA
Percentage of Pregnancies With Hydrops Fetalis
기간: Up to 41 weeks PMA

Percentage of pregnancies with hydrops fetalis will be reported. Hydrops fetalis is defined as the presence of >=2 abnormal fluid collections in the fetus or neonate, such as ascites, pleural effusions, pericardial effusion, and generalized skin edema (skin thickness >5 mm).

Up to 41 weeks PMA
Percentage of Pregnancies Receiving IUT During Pregnancy
기간: Up to 35 weeks of GA period

Percentage of pregnancies receiving IUT during pregnancy will be reported.

Up to 35 weeks of GA period
Gestational Age (GA) at First IUT
기간: Up to 35 weeks of GA period

GA at first IUT will be reported.

Up to 35 weeks of GA period
Percentage of Pregnancies Receiving >1 IUT During Pregnancy
기간: Up to 35 weeks of GA period

Percentage of pregnancies receiving >1 IUT during pregnancy will be reported.

Up to 35 weeks of GA period
Percentage of Pregnancies Receiving IUT or HDFN Resulting in Fetal Demise (Less Than) <GA Week 20
기간: Up to 20 weeks

Percentage of pregnancies receiving IUT or HDFN resulting in fetal demise <GA Week 20 will be reported.

Up to 20 weeks
Gestational Age at Delivery
기간: Up to 38 weeks

Gestational age at delivery will be reported.

Up to 38 weeks
Percentage of Pregnancies With Neonatal Death Through the Neonatal Period
기간: From randomization in the study through 4 weeks of age or 41 weeks PMA during neonatal period, whichever is later

Percentage of pregnancies with neonatal death through the neonatal period will be reported.

From randomization in the study through 4 weeks of age or 41 weeks PMA during neonatal period, whichever is later
Percentage of Liveborn Neonates With HDFN-related Morbidities Other Than Anemia and Hyperbilirubinemia or Jaundice
기간: From day of birth up to 4 weeks

Percentage of liveborn neonates with HDFN-related morbidities other than anemia and hyperbilirubinemia or jaundice will be reported.

From day of birth up to 4 weeks
Absolute Weight of Liveborn Neonates or Infants
기간: Up to 104 weeks

Absolute weight of liveborn neonates or infants will be reported.

Up to 104 weeks
Change From Baseline in Weight of Liveborn Neonates or Infants
기간: Baseline to up to 104 weeks

Change from baseline in weight of liveborn neonates or infants will be reported.

Baseline to up to 104 weeks
Liveborn Neonates Length of Stay in Neonatal Intensive Care Unit
기간: From day of birth up to 27 days

Liveborn neonates length of stay in neonatal intensive care unit will be reported.

From day of birth up to 27 days
Percentage of Liveborn Neonates Receiving Exchange Transfusions for HDFN
기간: From day of birth up to 27 days

Percentage of liveborn neonates receiving exchange transfusions for HDFN will be reported.

From day of birth up to 27 days
Number of Neonatal Exchange Transfusions per Liveborn Neonate
기간: From day of birth up to 27 days

Number of neonatal exchange transfusions per liveborn neonate will be reported.

From day of birth up to 27 days
Percentage of Liveborn Neonates or Infants with Simple Transfusions for HDFN
기간: For first database lock: From birth up to 4 weeks; for second database lock: From birth up to 12 weeks

Percentage of liveborn neonates or infants with simple transfusions for HDFN through the neonatal period (for the first database lock) or 12 weeks (for the second database lock) after birth will be reported.

For first database lock: From birth up to 4 weeks; for second database lock: From birth up to 12 weeks
Number of Simple Transfusions for HDFN per Liveborn Neonate or Infant
기간: For first database lock: From birth up to 4 weeks; for second database lock: From birth up to 12 weeks

Number of simple transfusions for HDFN per liveborn neonate or infant through the neonatal period (for the first database lock) or 12 weeks (for the second database lock) after birth will be reported.

For first database lock: From birth up to 4 weeks; for second database lock: From birth up to 12 weeks
Percentage of Liveborn Neonates With Hyperbilirubinemia Treated With Phototherapy
기간: From day of birth up to 27 days

Percentage of liveborn neonates with hyperbilirubinemia treated with phototherapy will be reported.

From day of birth up to 27 days
Number of Days of Phototherapy Received for Hyperbilirubinemia per Liveborn Neonate
기간: From day of birth up to 27 days

Number of days of phototherapy received for hyperbilirubinemia per liveborn neonate will be reported.

From day of birth up to 27 days
Percentage of Liveborn Neonates or Infants Receiving Intravenous Immunoglobulin (IVIg) for HDFN Treatment
기간: For first database lock: From birth up to 4 weeks; for second database lock: From birth up to 12 weeks

Percentage of liveborn neonates or infants receiving IVIg for HDFN treatment will be reported.

For first database lock: From birth up to 4 weeks; for second database lock: From birth up to 12 weeks
Number of Maternal Deaths
기간: Form randomization up to 24 weeks postpartum

Number of maternal deaths will be reported.

Form randomization up to 24 weeks postpartum
Number of Participants with Adverse Events (AEs)
기간: From randomization up to 24 weeks postpartum

Number of participants with AEs, serious adverse events, and AEs of special interest (AESIs), AE's leading to discontinuations, infections, serious infections, infusion reactions, and hypersensitivity reactions will be reported. Treatment-emergent adverse events associated with the following situations are considered as AESIs: hypoalbuminemia, clinically significant bleeding with a corresponding placental finding on ultrasound, maternal infections that led to clinically significant morbidities or mortalities in fetus or neonates, Infections that are severe or require intravenous (IV) anti-infective or operative or invasive intervention in maternal participants or neonates or infants, and infants with hypogammaglobulinemia.

From randomization up to 24 weeks postpartum
Number of Maternal Pregnancy Complications
기간: Up to 38 weeks

Number of maternal pregnancy complications will be reported.

Up to 38 weeks
Number of IUT Related complications
기간: Up to 35 weeks of GA period

Number of participants with IUT related complications will be reported.

Up to 35 weeks of GA period
Percentage of Pregnancies With Cesarean Delivery, Preterm Birth, Fetal Growth, and Preeclampsia
기간: Up to 38 weeks of GA period

Percentage of pregnancies with cesarean delivery, cesarean delivery due to IUT complications, preterm birth <GA week 28, preterm birth <GA week 32, preterm birth <GA week 34, preterm birth <GA week 37, fetal growth restriction, and preeclampsia will be reported.

Up to 38 weeks of GA period
Percentage of Liveborn Neonates or Infants Who Died
기간: Up to 104 weeks

Percentage of liveborn neonates or infants who died will be reported.

Up to 104 weeks
Percentage of Liveborn Neonates or Infants With AEs
기간: Up to 104 weeks

Percentage of liveborn neonates or infants with AEs, SAEs, AESIs, infections, serious infections will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. Any event requiring hospitalization (or prolongation of hospitalization) that occurs during participation in the study must be reported as an SAE.

Up to 104 weeks
Percentage of Liveborn Neonates or Infants Receiving IVIg for Non-HDFN Indications
기간: Up to 104 weeks

Percentage of liveborn neonates or infants receiving IVIg for non-HDFN indications will be reported.

Up to 104 weeks
Percentage of Liveborn Neonates or Infants With Abnormal Hearing
기간: Up to 104 weeks

Percentage of liveborn neonates or infants with abnormal hearing will be reported.

Up to 104 weeks
Bayley Scales of Infant Development and Toddler Development
기간: Week 52 and 104

The Bayley Scales of infant development is considered the standard assessment of early child development and includes cognition, language, motor skills, social emotional, and adaptive behavior will be reported. The Bayley Scales (3rd edition) are reference standards that measure infant and toddler development in five areas: cognition, language, motor skills, social-emotional and adaptive behavior. The cognition, language and motor skills scales are directly administered to the infant, while social-emotional, and adaptive behavior scales are caregiver questionnaires. The scores are standardized using norm reference samples with representative demographics and age adjusted for prematurity. Higher scores in the Bayley Scales indicate better outcomes.

Week 52 and 104
Change From Baseline in Generalized Anxiety Disorder 7-Item (GAD7) Over time During Pregnancy and Postpartum
기간: Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum

Change from baseline in GAD7 over time during pregnancy and postpartum will be reported. The GAD-7 scale is a self-administered questionnaire designed to measure anxiety. The recall period for all items is the past 2 weeks. Responses to all items are rated on a 4-point Likert scale ranging from 0 "not at all" to 3 "nearly every day". The total score ranges from 0 to 21, with higher scores indicating higher severity of anxiety symptoms.

Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum
Change From Baseline in Short Form 36 Version 2 (SF-36v2) Acute Form Domain Score
기간: Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum

Change from baseline in SF-36v2 acute form domain score will be reported. The SF-36 version 2 acute is a self-administered, 36-item questionnaire measuring health-related quality of life and includes 8 domains that measure physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality social functioning, role limitations due to emotional problems, and mental health. The 8 domains can be aggregated into 2 summary scales that reflect physical and mental health: a physical component summary and a mental component summary. Responses to all items are rated on a 3, 5, or 6-point Likert scale, with higher scores indicating better health status.

Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum
Change From Baseline in EuroQol Five-dimension Questionnaire (EQ-5D-5L) Visual Analogue Scale (VAS) Score
기간: Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum

Change from baseline in EQ-5D-5L visual analogue score will be reported. The EQ-5D descriptive system is comprised of 5 items across the following 5 dimensions: mobility, self-care, usual activities, pain or discomfort and anxiety or depression. The EQ-5D-5L uses a 5-point Likert response scale ranging from "no problems" to "extreme problems", with higher scores indicating better quality of life. EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ-VAS). EQ-VAS score ranges from 0 to 100, where 0 = worst imaginable health state and 100 = best imaginable health state. Higher score indicates good health state.

Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum
Change From Baseline in EuroQol 5-Dimension Descriptive (EQ-5D) Index Score
기간: Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum

Change from baseline in EQ-5D index score will be reported. The EQ-5D descriptive system is comprised of 5 items across the following 5 dimensions: mobility, self-care, usual activities, pain or discomfort and anxiety or depression. The EQ-5D-5L descriptive system uses a 5-point Likert response scale ranging from "no problems" to "extreme problems", with higher scores indicating better quality of life.

Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum
Infant Health-Related Quality of Life Instrument (IQI) Score for Neonate or Infant Overtime
기간: Weeks 4, 8 and 52

IQI score for neonate or infant will be reported. The IQI consists of 7 health attributes including sleeping, feeding, breathing, stooling or poo, mood, skin, and interaction. Responses to all items are rated on a 4-point Likert scale, with higher scores indicating better quality of life.

Weeks 4, 8 and 52

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 12월 20일

기본 완료 (추정된)

2027년 8월 5일

연구 완료 (추정된)

2029년 10월 8일

연구 등록 날짜

최초 제출

2023년 6월 13일

QC 기준을 충족하는 최초 제출

2023년 6월 13일

처음 게시됨 (실제)

2023년 6월 22일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 2일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • CR109199
  • 2021-002359-12 (EudraCT 번호)
  • 80202135EBF3001 (기타 식별자: Janssen Research & Development, LLC)
  • 2022-502629-16-00 (레지스트리 식별자: EUCT number)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다